Medical Research & Findings

   •   New blood test can predict breast cancer five years before it develops

   •   Olive oil may prevent cancer, study finds

 

(Lentz Therapy, Immunopheresis, UltraPheresis cancer therapy)

 • IMMUNOAPHERESIS Refers to the process of antibody cleansing.

 • APHERESIS Process in which blood is drawn from a person, separated into various components, then returned to the patients.

 • PLASMA Your blood is made up of a liquid portion and a cellular portion. The cellular portion contains white blood cells that fight infection, red blood cells that carry oxygen, and platelets that aid clotting. Plasma is the liquid portion of your blood. It has a number of vital functions in bleeding and infection control. It contains proteins and antibodies, which are produced by the immune system to fight diseases. sTNFRI block the immune system’s ability to recognize cancer cells and allow the cancer to grow.

 

UltraPheresis cancer therapy is based on the use of a blood filtration system developed by Dr. M. Rigdon Lentz, an American oncologist practicing now in Germany.

 

Simply put, UltraPheresis cleans the blood of decoys which cancer cells use to hide from the immune system. The immune system can then attack and kill cancer cells on its own.

 

This treatment is effective, safe and non-toxic.

 

This represents a new paradigm for cancer treatment; many feel it is worthy of the Nobel Prize in medicine.

 

To find out more about how the EuroMed Foundation uses Lentz therapy for holistic cancer treatment, click here to request your free personal orientation online. One of our doctors will be happy to answer general questions in person or over the phone.

 

How does UltraPheresis Therapy Work?

The immune system has a surveillance function called the Tumor Necrosis Factor (TNF). The immune system deploys an army of proteins designed to recognize and destroy tumor cells.

 

But smart cancer cells escape detection. They produce and shed immune system inhibitors into the bloodstream. These inhibitors are called soluble tumor necrosis factor receptors (sTNFR) and these are overproduced in cancer patients.

 

Dr. Lentz devised a method of treatment, somewhat like kidney dialysis, to remove sTNFRI from the bloodstream.

 

When plasma is separated from a cancer patient’s blood, filtered, then run through a device impregnated with antibodies, these inhibitors are removed, enabling the immune system to attack the tumors. The patient experiences inflammation in the tumors and a flu-like feeling. Over time the tumors shrink, often in short order.

 

Depending upon the person, this treatment is used as a stand-alone treatment or in conjunction with other cancer treatment alternatives, such as surgery and/or low dose insulin potentiated chemotherapy.

 

It is widely agreed that cancer is a failure of the immune system. UltraPheresis therapy is an immune system normalizing therapy. It is non-toxic, and straight-forward. It treats close to the root cause of the problem.

 

At our Arizona cancer center, patients are typically treated for two hours per day, five days per week. Patient progress is continuously monitored. The full treatment generally takes two to three months. The main side-effect of this treatment is pain from the person’s own appropriate immune system response destroying the cancer cells.

 

Dr. Lentz’s clinical experience demonstrates that complete tumor destruction is certainly possible through this treatment. He believes the potential for cancer recurrence is decreased. If a cancer recurs, it is responsive to repeating this therapy.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dr. M. Rigdon Lentz

Dr. LentzThis patented technology was developed by American-born and American-trained oncologist Rigdon Lentz, MD. He currently resides in Bavaria, Germany.

 

Dr. Lentz is affiliated with the Lombardi Center for Immunology at Georgetown University in Washington, D.C. He collaborates with physicians at the Karolinska Institute in Stockholm, Sweden in the research area of tumor immunology. He is the former chief of hematology and oncology at the Comprehensive Cancer Center of Valdosta, GA and the former director of the Nashville, TN, Apheresis Center.

 

In the late 1980s, Dr. Lentz carried out FDA-supervised Phase I and Phase II studies. In the Proceedings of the National Academy of Sciences, Lentz and colleagues identified, purified, and characterized immune system inhibitors found in the blood of cancer patients.[1]

 

Dr. Lentz spent two decades investigating the ability of cancer to turn off an otherwise-normal immune system. Attempting to physically remove blocking factors, he custom built a machine that filters them out of the cancer patient’s bloodstream.

 

Dr. Lentz founded Biopheresis Technologies Inc, a U.S. company, and its wholly owned operating company, Biopheresis GmbH, located in Heidelberg, Germany.

 

In April, 2008, the device received the C.E. Mark (“Conformite Europeenne”). This is a European marking certifying that a product has met EU health, safety, and environmental requirements for consumer safety. At this time, 32 countries recognize the C.E. Mark. The United States does not recognize the C.E. Mark; the FDA is often slow to approve non-toxic treatments and this is one reason so many Americans go to Europe for treatment.

 

Cancer treatment alternatives to radiation or chemotherapy would be a welcome addition to the arsenal of weapons for the war against cancer. Drug based therapies are based on discovery of molecules to poison or block a single biological event in order to kill a cancer cell. The UltraPheresis treatment however, is based on the removal of soluble immuno-inhibitors known to interfere with the most powerful agent of the body’s own innate immune system that acts against cancers, TNF.

 

A small amount of inhibitors occupying a normal cell structure.

A cancer cell that has shed a massive amount of tumor necrosis inhibitors to cover itself. Outside the cell, the red item represents the TNF (tumor necrosis factor).

STORE

The TNF being made inert through binding of inhibitors.

DONATE NOW

© 2017 Michelle Lynn Holsey Foundation

Website & hosting by Vicki LeBlanc